NEW YORK (GenomeWeb News) – Becton Dickinson and Fujirebio Diagnostics have inked a worldwide development and supply agreement for multiplex oncology diagnostic assays.

The firms said today that they will develop diagnostic products that contain Fujirebio's biomarkers that will run on BD's multiplex testing platform. Initial efforts will focus on the ovarian cancer biomarker HE4, which is cleared by the Food and Drug Administration for monitoring the progression or recurrence of epithelial ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.